Selling Your Veterinary Practice to PetVet Care Centers: A Vet’s 2026 Guide

Key takeaways

• PetVet Care Centers is one of the largest US veterinary practice consolidator platforms, headquartered in Westport, Connecticut and founded in 2014.
• Ares Management is the current financial sponsor per public ownership disclosures — a global alternative investment manager whose institutional scale supports PetVet’s sustained acquisition program.
• Local brand preservation is the platform’s stated approach per PetVet company materials. Acquired practices typically retain their original identity post-acquisition.
• The institutional scale dimension is what most distinguishes PetVet from mid-market PE-backed competitors. The Ares sponsorship brings governance depth and capital flexibility that smaller platforms cannot match — but the same scale generates standardized cost allocations that deserve careful protective provisions in any partnership or earnout structure.
• The most reliable way to know what PetVet — or any major buyer — would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. PetVet is invited inside that rope on practices that fit their criteria — and when they bid against a curated group of qualified competitors, the number is reliably very different from what they would offer in a direct, single-bidder conversation.

The PetVet conversation tends to open with a discussion about scale. PetVet is one of the few US veterinary platforms whose financial sponsor — Ares Management — sits among the largest alternative investment managers globally, and that institutional weight shows up in how the platform operates: centralized procurement at meaningful scale, established governance infrastructure, sustained acquisition cadence backed by deep capital.

For practice owners weighing offers, that scale signals stability. It also signals that the operational integration mechanics post-close are highly standardized, which is both a strength and a negotiation surface.

What follows is the picture I’d lay out over dinner if a vet handed me a PetVet offer and asked what to do with it. Who PetVet is, what the Ares-backed institutional scale means for sellers, where the negotiation leverage actually sits given that scale, and how to think about PetVet against the rest of the US veterinary buyer pool in a properly run process.

Quick facts on PetVet Care Centers

PetVet Care Centers was founded in 2014 and has grown into one of the largest US veterinary practice consolidator platforms by hospital count. The company’s headquarters are in Westport, Connecticut.

PetVet operates a mix of general practice and specialty hospitals across multiple US regions per PetVet company materials.

Ownership. PetVet is sponsored by Ares Management per public ownership disclosures. Ares is a Los Angeles-based global alternative investment manager with substantial private equity, credit, and real estate activity globally — one of the larger alternative-asset platforms by AUM.

The Ares sponsorship of PetVet followed a prior period under KKR ownership per trade press documentation. The transition between institutional sponsors at PetVet — like the transitions at VetCor — is itself a feature: the platform has demonstrated liquidity-event capacity that newer, never-exited platforms have not.

Most important practical fact. PetVet’s institutional scale is the distinguishing dimension. The platform’s central infrastructure — procurement, IT, HR, accounting, marketing, clinical-protocol development — operates at a depth that mid-market PE-backed competitors typically cannot match.

That delivers genuine operational savings to acquired practices. It also imposes standardized operational defaults that the seller’s earnout and clinical-autonomy provisions need to be negotiated against.

What PetVet actually pays for veterinary practices in 2026

The consistent pattern we see. When a multi-doctor practice receives a direct offer from any major buyer — PetVet included — the offer reflects the leverage the buyer perceives in the conversation. A single bidder facing no visible competition has no structural reason to put forward their strongest cash percentage, tightest earnout protections, most explicit operational protective provisions, or most flexible clinical-autonomy carve-outs in the first conversation.

Inside a properly structured competitive process those dimensions tend to move. The pattern is the same across the institutional buyer pool; PetVet’s bidding behavior under competitive pressure is consistent with that broader dynamic.

PetVet does not publish a standard price sheet. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range typically land in the low-teens EBITDA range across the major buyer pool.

The actual number for any specific practice depends heavily on whether other buyers are at the table.

For specialty and emergency hospitals, broader market values these higher than comparable GP practices per industry research. PetVet’s specialty footprint has expanded over the years and the platform may bid for qualifying specialty platforms.

For larger multi-location groups ($10 million-plus revenue), the multiple range typically extends higher, with deal sizes scaling into the eight-figure-plus range. PetVet’s institutional capital position from Ares is one of the strongest in the US veterinary buyer pool for larger platform acquisitions.

The cash-at-close reality

PetVet’s institutional capital position generally supports competitive cash-at-close percentages in their offers. Per industry M&A commentary across the major buyer pool (Dechert LLP, Holland & Knight, Capstone Partners 2025-2026), typical structure allocates the majority of total deal value to cash at close, with the remainder split among earnout, rollover equity, and occasional seller notes.

The Ares sponsorship matters for the rollover-equity component specifically. A rollover into PetVet equity sits inside a platform with documented institutional ownership transitions (KKR exit to Ares) — not a hypothetical first exit.

That doesn’t change the formula price or the put/call window in any specific deal, but it does change the probability picture a seller can reasonably underwrite. For sellers comparing PetVet rollover to a rollover into a newer PE-backed platform that has never been through a sponsor exit, the documented track record is a meaningful underwriting factor.

A note on deal structure types in the current market

The US veterinary M&A market has shifted toward partnership and joint-venture structures over the past 18 months per MB Law Firm’s 2025 healthcare M&A commentary. Mission Pet Health (legacy SVP), AmeriVet, Rarebreed, and others publicly emphasize partnership variants in their company materials.

PetVet’s specific posture on partnership versus 100-percent acquisition is determined case by case under confidentiality. Sellers evaluating a PetVet offer should ask whether a partnership structure is available alongside the more traditional 100-percent acquisition.

Our PE pricing guide covers the structure comparison.

How PetVet’s acquisition team operates

PetVet’s corporate-development team operates across the standard channels — direct outreach to practice owners identified through industry data and broker relationships, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries. The team’s institutional backing means it tends to engage substantively when the seller-side process reflects sophistication.

The depth of Ares’s healthcare investment infrastructure also means PetVet’s diligence runs deeper than smaller mid-market acquirers — the deal-team’s underwriting standards are closer to large-cap healthcare PE than to lower-middle-market roll-up patterns.

How PetVet integrates the practices it acquires

PetVet’s integration approach combines operational depth with brand-preservation across the network.

Local brand preservation. Per PetVet company materials, the platform’s general approach is to preserve the practice name, signage, marketing materials, and local identity. Integration emphasizes back-office and operational dimensions rather than customer-facing brand consolidation.

Shared back office at scale. Centralized HR, accounting, payroll, vendor management, supply purchasing, marketing infrastructure, and IT support operate at platform scale across the network. PetVet’s institutional capital base supports deeper central-services infrastructure than mid-market competitors.

Centralized procurement. PetVet’s purchasing scale delivers documented cost reductions for diagnostics, pharmaceuticals, equipment, and operational supplies. The earnout-window implication runs both directions: lower variable costs can raise practice-level EBITDA, but central procurement decisions that override seller preferences need protective contractual language.

Continuing education and clinical programs. PetVet has built institutional continuing-education and clinical-development programming per company materials. The platform scale supports broader CE offerings than smaller PE-backed competitors.

Doctor relationships. Per industry M&A commentary, selling owners commonly stay on as medical director for 3 to 5 years post-close. PetVet’s specific post-sale employment terms for any deal are negotiated case by case.

PetVet’s recent activity in 2025-2026

PetVet remains one of the most active US veterinary acquirers entering 2026. Capstone Partners‘ April 2026 Pet Sector M&A Update documents sector acceleration in Q1 2026, with PetVet visible in trade press as an active platform.

Specific acquisition counts are not publicly itemized in real time. The Ares-backed capital position supports sustained pipeline depth, which means PetVet is consistently inside the bidder pool for qualifying practices.

Have an offer from PetVet? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms, identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process. No upfront cost, no obligation.

How PetVet compares to the other major buyers

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic family-owned exception — structurally distinct from PetVet’s PE-backed model. Brand-handling differs (VCA consolidates under VCA brand; PetVet preserves local identity).

Our Mars Veterinary Health buyer profile covers Mars-specific dimensions.

Versus NVA (JAB Holdings). NVA is a long-hold strategic, distinguishable from PE-fund-cycle PetVet. Both preserve local branding.

Our NVA buyer profile covers NVA-specific dimensions.

Versus VetCor (Harvest Partners). VetCor has the longest-tenured PE-backed track record in the US veterinary platform pool. Both PetVet and VetCor preserve local branding.

PetVet’s Ares-backed institutional scale and VetCor‘s institutional longevity are different versions of “established platform” — the choice depends on specific deal terms and geographic fit. Our VetCor buyer profile walks through VetCor’s institutional dimensions.

Versus AmeriVet and Mission Pet Health. Both AmeriVet and Mission Pet Health emphasize partnership / co-ownership structures as a default; PetVet’s default leans more toward 100-percent acquisition with rollover. For sellers preferring partnership structures, AmeriVet or Mission Pet Health is the natural comparison.

Our AmeriVet buyer profile and the Mission Pet Health profile cover the partnership-model dimensions.

Versus smaller PE-backed groups (Thrive Pet Healthcare, Alliance Animal Health, Heartland, VPP, Rarebreed, others). Smaller groups sometimes pay more aggressively for practices that fill specific geographic or specialty gaps. Right way to compare is in a competitive process where everyone surfaces their best offers in parallel.

What to negotiate before signing with PetVet

Six priorities when negotiating with PetVet’s acquisition team.

Central-services cost-allocation protective provisions (highest priority). PetVet’s scale delivers real procurement and infrastructure savings, but the allocation of central-services costs to the acquired practice during the earnout window is a critical surface. Negotiate explicit caps on cost allocations, prohibition on shifting costs from other PetVet practices to your practice, and clear definition of what counts in the EBITDA calculation at the earnout date.

Cash at close percentage. Push for higher cash percentages. PetVet’s institutional capital position generally supports flexibility on this dimension when the process is competitive.

Earnout structure. Earnouts commonly run on multi-year EBITDA targets. Push for shorter duration, revenue-based metrics where possible, and the standard protective clauses (no major operational changes without consent, working capital floor).

Rollover equity terms. If PetVet’s offer includes rollover, the documented Ares-led ownership history (KKR exit to Ares) provides a more concrete underwriting basis than a never-exited platform. Negotiate the standard protections: defined liquidity windows, governance rights, anti-dilution provisions.

Non-compete scope and post-sale clinical autonomy. PetVet’s standardized clinical protocols may differ from existing practice approaches. Negotiate explicit clinical-autonomy language (you make medicine decisions, not the regional team) and tighten non-compete duration and radius.

Brand preservation in writing. PetVet’s stated approach is local brand preservation. Negotiate explicit brand-preservation language in the definitive purchase agreement rather than relying on the “general approach” framing from marketing materials.

The institutional-scale question, in depth

For sellers evaluating PetVet specifically, the most useful frame is to think clearly about what Ares-backed institutional scale means for the practical post-sale practice life.

The case for scale. PetVet’s institutional infrastructure delivers documented benefits: lower input costs through centralized procurement, deeper continuing-education resources, more robust IT and back-office support, and platform stability backed by one of the larger alternative-asset managers globally. For owners who want to step back from non-clinical responsibilities post-sale, the operational depth removes a meaningful amount of practice-management burden.

The case for scale as a negotiation surface. The same institutional infrastructure imposes standardized defaults across the network. Central-services cost allocations follow platform-level methodologies.

Vendor consolidation happens on platform timelines. Clinical-protocol standardization reflects accumulated network experience.

Each of these touches practice-level economics during the earnout window. The protective contractual provisions that govern these touch points are where the negotiation leverage lives.

The balance depends on the specific seller. Owners who value operational simplification post-sale tend to land well at PetVet with relatively modest protective provisions.

Owners who want maximum control over post-close practice operations need sharper contractual provisions to preserve that control inside the institutional platform. A properly run competitive process surfaces both options across multiple bidders so the seller can compare directly.

Should I take a PetVet offer or run a competitive process?

For PetVet specifically, the value of the competitive process is concentrated in the operational-integration protective provisions rather than the headline multiple. PetVet’s institutional capital generally supports competitive cash percentages even in direct conversations.

Where the competitive process produces leverage is on the central-services cost-allocation clauses, the clinical-autonomy carve-outs, the earnout protective provisions, the brand-preservation guarantees, and the non-compete scope. Each of those dimensions moves only under competitive pressure.

PetVet participates in well-run competitive processes when invited. The PetVet-specific dimensions get sharper attention from the team when they know other qualified buyers are at the table on the same practice in the same window.

What our Elite Selling System actually does

For a PetVet-affiliated transaction, our process centers on the contractual clauses where the platform’s institutional defaults intersect with the seller’s post-sale autonomy.

Phase one — the operational-defaults audit. Before any bidder packet goes out, we deconstruct PetVet’s standard template clauses against the comparable templates we’ve seen from VetCor, NVA, Mars-affiliated entities, AmeriVet, and the other major buyers. Where do PetVet’s central-services cost allocations sit against the field?

What clinical-autonomy language is in their draft, and which protective clauses are softer than the standards we’ve seen in well-negotiated peer transactions? This audit identifies the negotiation surface before the competitive process opens.

Phase two — the curated bidder mix. From the 42-plus veterinary consolidators TE tracks, we invite only the ones whose profile genuinely competes with PetVet for this specific practice — institutional-scale competitors (Mars-affiliated entities, NVA, the largest PE-backed platforms), mid-market alternatives offering different structural variants, and partnership-emphasis competitors that offer a different deal-shape entirely. The bidder mix is typically 5 to 7 invited buyers covering structural alternatives.

Phase three — the term-by-term comparison. Bidders return their full term sheets. The seller sees side-by-side comparisons across every dimension.

PetVet either matches the best terms across the field or loses on dimensions they don’t have to lose on. Either outcome is better for the seller than the original direct offer would have produced.

The economic result holds across deal types: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes — typically multiple seven figures, sometimes more — than the same practice would have cleared by signing the original direct PetVet term sheet without exploring the field.

Closing thought

PetVet Care Centers enters 2026 as one of the largest and most institutionally backed US veterinary platforms, with Ares Management‘s capital depth supporting sustained acquisition activity and operational infrastructure that mid-market competitors generally cannot match. The platform’s scale delivers genuine post-sale operational benefits to acquired practices — and imposes standardized institutional defaults that the seller’s contractual protections need to be negotiated against.

What separates a well-negotiated PetVet outcome from a mediocre one isn’t the cash multiple — PetVet’s institutional capital generally supports competitive cash. It’s the central-services cost-allocation provisions, the clinical-autonomy carve-outs, the brand-preservation guarantees, and the earnout protective clauses.

Those terms determine whether the institutional platform works in the seller’s favor or against it across the post-close years.

If a PetVet offer is on your desk right now — or if PetVet’s team has reached out to start the conversation — the highest-leverage move is to understand how the rest of the field would structure the same practice on different operational-integration terms before committing to anything. Get a Free Practice Value Estimate and we’ll lay out the same operational-clause comparison we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

PetVet Care Centers and parent company materials

6. PetVet Care Centers. About PetVet and US footprint. PetVet company materials, 2024-2026.
7. Ares Management. Portfolio and healthcare services investment practice. Ares company materials.

Veterinary practice operations, benchmarks, and profession data

8. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
9. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.